224 related articles for article (PubMed ID: 37059907)
1. Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets.
Bacabac M; Xu W
Cancer Metastasis Rev; 2023 Jun; 42(2):471-480. PubMed ID: 37059907
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Lovén J; Hoke HA; Lin CY; Lau A; Orlando DA; Vakoc CR; Bradner JE; Lee TI; Young RA
Cell; 2013 Apr; 153(2):320-34. PubMed ID: 23582323
[TBL] [Abstract][Full Text] [Related]
3. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
4. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
5. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J
Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439
[TBL] [Abstract][Full Text] [Related]
6. Etiology of super-enhancer reprogramming and activation in cancer.
Zhou RW; Parsons RE
Epigenetics Chromatin; 2023 Jul; 16(1):29. PubMed ID: 37415185
[TBL] [Abstract][Full Text] [Related]
7. Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer.
Zuber V; Bettella F; Witoelar A; ; ; ; ; Andreassen OA; Mills IG; Urbanucci A
BMC Genomics; 2017 Mar; 18(1):270. PubMed ID: 28359301
[TBL] [Abstract][Full Text] [Related]
8. Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes.
Dooley KE; Warburton A; McBride AA
mBio; 2016 Sep; 7(5):. PubMed ID: 27624132
[TBL] [Abstract][Full Text] [Related]
9. Super-enhancers in cancer.
Thandapani P
Pharmacol Ther; 2019 Jul; 199():129-138. PubMed ID: 30885876
[TBL] [Abstract][Full Text] [Related]
10. The molecular understanding of super-enhancer dysregulation in cancer.
Yoshino S; Suzuki HI
Nagoya J Med Sci; 2022 May; 84(2):216-229. PubMed ID: 35967935
[TBL] [Abstract][Full Text] [Related]
11. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.
Tsang FH; Law CT; Tang TC; Cheng CL; Chin DW; Tam WV; Wei L; Wong CC; Ng IO; Wong CM
Hepatology; 2019 Jun; 69(6):2502-2517. PubMed ID: 30723918
[TBL] [Abstract][Full Text] [Related]
12. BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance.
Tasdemir N; Banito A; Roe JS; Alonso-Curbelo D; Camiolo M; Tschaharganeh DF; Huang CH; Aksoy O; Bolden JE; Chen CC; Fennell M; Thapar V; Chicas A; Vakoc CR; Lowe SW
Cancer Discov; 2016 Jun; 6(6):612-29. PubMed ID: 27099234
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells.
Wiese M; Hamdan FH; Kubiak K; Diederichs C; Gielen GH; Nussbaumer G; Carcaboso AM; Hulleman E; Johnsen SA; Kramm CM
Cell Death Dis; 2020 Aug; 11(8):673. PubMed ID: 32826850
[TBL] [Abstract][Full Text] [Related]
14. Multifaceted regulation of enhancers in cancer.
Xiao Q; Xiao Y; Li LY; Chen MK; Wu M
Biochim Biophys Acta Gene Regul Mech; 2022 Aug; 1865(6):194839. PubMed ID: 35750313
[TBL] [Abstract][Full Text] [Related]
15. Core regulatory circuitries in defining cancer cell identity across the malignant spectrum.
Jahangiri L; Tsaprouni L; Trigg RM; Williams JA; Gkoutos GV; Turner SD; Pereira J
Open Biol; 2020 Jul; 10(7):200121. PubMed ID: 32634370
[TBL] [Abstract][Full Text] [Related]
16. Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor.
Zhang J; Liu W; Zou C; Zhao Z; Lai Y; Shi Z; Xie X; Huang G; Wang Y; Zhang X; Fan Z; Su Q; Yin J; Shen J
Clin Cancer Res; 2020 Jun; 26(11):2681-2692. PubMed ID: 31937612
[TBL] [Abstract][Full Text] [Related]
17. Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets.
Qian H; Zhu M; Tan X; Zhang Y; Liu X; Yang L
Cell Death Discov; 2023 Dec; 9(1):470. PubMed ID: 38135679
[TBL] [Abstract][Full Text] [Related]
18. Super-enhancers in the control of cell identity and disease.
Hnisz D; Abraham BJ; Lee TI; Lau A; Saint-André V; Sigova AA; Hoke HA; Young RA
Cell; 2013 Nov; 155(4):934-47. PubMed ID: 24119843
[TBL] [Abstract][Full Text] [Related]
19. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
20. Super enhancers - new analyses and perspectives on the low hanging fruit.
Hamdan FH; Johnsen SA
Transcription; 2018; 9(2):123-130. PubMed ID: 28980882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
